董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles S. McKhann | 男 | Director | -- | 8.76万美元 | 未持股 | 2026-03-10 |
| John Aballi | -- | Chief Executive Officer and Director and President | -- | 140.09万美元 | 53.47 | 2026-03-10 |
| Ana Hooker | -- | Director | -- | 13.19万美元 | 4.20 | 2026-03-10 |
| Paul Kim | -- | Director | -- | 13.00万美元 | 3.22 | 2026-03-10 |
| Frank Stokes | -- | Director | -- | 12.63万美元 | 5.10 | 2026-03-10 |
| Scott D. Kahn | -- | Director | -- | 13.00万美元 | 1.90 | 2026-03-10 |
| Bruce C. Robertson | 男 | Director | 65 | 未披露 | 169.63 | 2026-03-10 |
| Tina S. Nova | 女 | Executive Chairman of the Board | 72 | 19.82万美元 | 8.11 | 2026-03-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Aballi | -- | Chief Executive Officer and Director and President | -- | 140.09万美元 | 53.47 | 2026-03-10 |
| Jeffrey G. Black | -- | Chief Financial Officer and Corporate Secretary | -- | 74.62万美元 | 9.21 | 2026-03-10 |
| Tina S. Nova | 女 | Executive Chairman of the Board | 72 | 19.82万美元 | 8.11 | 2026-03-10 |
董事简历
中英对照 | 中文 | 英文- Charles S. McKhann
-
Charles S. McKhann，曾于2023年11月至2024年9月Silk Road被波士顿科学国际有限公司（“波士顿科学”）购买时担任医疗器械公司Silk Road Medical, Inc.（“Silk Road”）的总裁、首席执行官、董事会成员，并于2021年3月至2023年4月4日Apollo被波士顿科学购买时担任医疗器械公司Apollo Endosurgery, Inc.（“Apollo Endosurgery，Inc.”）的首席执行官、总裁、董事会成员。2017年10月至2018年12月，McKhann先生在医疗设备公司ROX Medical，Inc.担任首席商务官。2016年7月至2017年4月担任Torax Medical，Inc.首席商务官，该公司为2017年4月被强生收购的医疗器械公司。2015年1月至2016年7月，任医疗器械公司Intersect ENT，Inc.首席商务官。此外，2012年9月至2021年3月，他担任Vernon Consulting，Inc.的董事总经理。McKhann先生拥有政治学和经济学学士学位以及斯坦福大学的工商管理硕士学位。
Charles S. McKhann,served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical, Inc. ("Silk Road"), a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation ("Boston Scientific"), and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery, Inc. ("Apollo"), a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific. From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical, Inc., a medical device company. From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical, Inc., a medical device company acquired by Johnson & Johnson in April 2017. From January 2015 to July 2016, he served as Chief Commercial Officer of Intersect ENT, Inc., a medical device company. In addition, from September 2012 to March 2021, he served as Managing Director of Vernon Consulting, Inc. Mr. McKhann holds a B.A. in Political Sciences and Economics and an M.B.A. from Stanford University. - Charles S. McKhann，曾于2023年11月至2024年9月Silk Road被波士顿科学国际有限公司（“波士顿科学”）购买时担任医疗器械公司Silk Road Medical, Inc.（“Silk Road”）的总裁、首席执行官、董事会成员，并于2021年3月至2023年4月4日Apollo被波士顿科学购买时担任医疗器械公司Apollo Endosurgery, Inc.（“Apollo Endosurgery，Inc.”）的首席执行官、总裁、董事会成员。2017年10月至2018年12月，McKhann先生在医疗设备公司ROX Medical，Inc.担任首席商务官。2016年7月至2017年4月担任Torax Medical，Inc.首席商务官，该公司为2017年4月被强生收购的医疗器械公司。2015年1月至2016年7月，任医疗器械公司Intersect ENT，Inc.首席商务官。此外，2012年9月至2021年3月，他担任Vernon Consulting，Inc.的董事总经理。McKhann先生拥有政治学和经济学学士学位以及斯坦福大学的工商管理硕士学位。
- Charles S. McKhann,served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical, Inc. ("Silk Road"), a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation ("Boston Scientific"), and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery, Inc. ("Apollo"), a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific. From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical, Inc., a medical device company. From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical, Inc., a medical device company acquired by Johnson & Johnson in April 2017. From January 2015 to July 2016, he served as Chief Commercial Officer of Intersect ENT, Inc., a medical device company. In addition, from September 2012 to March 2021, he served as Managing Director of Vernon Consulting, Inc. Mr. McKhann holds a B.A. in Political Sciences and Economics and an M.B.A. from Stanford University.
- John Aballi
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Ana Hooker
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Paul Kim
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Frank Stokes
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Scott D. Kahn
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Bruce C. Robertson
-
Bruce C. Robertson，博士，自2007年11月起担任Exagen Inc.董事会成员。自2005年以来，他一直担任H.I.G。的董事总经理。BioVentures，一家风险投资公司。他之前曾担任早期风险投资公司Toucan Capital的董事总经理。Robertson博士还在许多私营公司和组织的董事会任职，包括CardioFocus，Inc.、Apollo Endosurgery、Mid-Atlantic Venture Association、Adventist Healthcare和特拉华大学研究基金会。Robertson博士获得了B.S.E。宾夕法尼亚大学化学/生物医学工程学士学位、哈佛商学院工商管理硕士学位和博士学位。来自特拉华大学。
Bruce C. Robertson, Ph.D. has served as a member of Exagen Inc.'s board of directors since November 2007. Since 2005 he has served as a Managing Director at H.I.G. BioVentures, a venture capital firm. He previously served as a Managing Director at Toucan Capital, an early-stage venture capital firm. Dr. Robertson also serves on the board of directors of a number of private companies and organizations, including Cardiofocus, Inc., Apollo Endosurgery, Mid-Atlantic Venture Association, Adventist Healthcare and the University of Delaware Research Foundation. Dr. Robertson received a B.S.E. in Chemical/Biomedical Engineering from the University of Pennsylvania, an M.B.A. from Harvard Business School, and a Ph.D. from the University of Delaware. - Bruce C. Robertson，博士，自2007年11月起担任Exagen Inc.董事会成员。自2005年以来，他一直担任H.I.G。的董事总经理。BioVentures，一家风险投资公司。他之前曾担任早期风险投资公司Toucan Capital的董事总经理。Robertson博士还在许多私营公司和组织的董事会任职，包括CardioFocus，Inc.、Apollo Endosurgery、Mid-Atlantic Venture Association、Adventist Healthcare和特拉华大学研究基金会。Robertson博士获得了B.S.E。宾夕法尼亚大学化学/生物医学工程学士学位、哈佛商学院工商管理硕士学位和博士学位。来自特拉华大学。
- Bruce C. Robertson, Ph.D. has served as a member of Exagen Inc.'s board of directors since November 2007. Since 2005 he has served as a Managing Director at H.I.G. BioVentures, a venture capital firm. He previously served as a Managing Director at Toucan Capital, an early-stage venture capital firm. Dr. Robertson also serves on the board of directors of a number of private companies and organizations, including Cardiofocus, Inc., Apollo Endosurgery, Mid-Atlantic Venture Association, Adventist Healthcare and the University of Delaware Research Foundation. Dr. Robertson received a B.S.E. in Chemical/Biomedical Engineering from the University of Pennsylvania, an M.B.A. from Harvard Business School, and a Ph.D. from the University of Delaware.
- Tina S. Nova
-
Tina S. Nova博士自2014年4月成为董事会的成员，同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.，这是一家医药实验室诊断公司，她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix，担任Genoptix的首席执行官，同时是Genoptix董事会成员。此前，Nova先生联合创建了Nanogen, Inc.，Nanogen, Inc.是一家分子诊断测试的提供商，她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前，Nova博士担任Selective Genetics的首席运营官，这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.（Eli Lilly & Company的前子公司）担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校（niversity of California, Irvine）获得生物科学学士学位。从加州大学里弗赛德分校（University of California, Riverside）获得生物化学博士学位。
Tina S. Nova has extensive experience in the creation of start up companies and the commercialization of products with a focus on molecular diagnostics. Dr. Nova spent 15 years as the co founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co founded a number of early stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc. - Tina S. Nova博士自2014年4月成为董事会的成员，同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.，这是一家医药实验室诊断公司，她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix，担任Genoptix的首席执行官，同时是Genoptix董事会成员。此前，Nova先生联合创建了Nanogen, Inc.，Nanogen, Inc.是一家分子诊断测试的提供商，她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前，Nova博士担任Selective Genetics的首席运营官，这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.（Eli Lilly & Company的前子公司）担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校（niversity of California, Irvine）获得生物科学学士学位。从加州大学里弗赛德分校（University of California, Riverside）获得生物化学博士学位。
- Tina S. Nova has extensive experience in the creation of start up companies and the commercialization of products with a focus on molecular diagnostics. Dr. Nova spent 15 years as the co founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co founded a number of early stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc.
高管简历
中英对照 | 中文 | 英文- John Aballi
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeffrey G. Black
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Tina S. Nova
Tina S. Nova博士自2014年4月成为董事会的成员，同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.，这是一家医药实验室诊断公司，她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix，担任Genoptix的首席执行官，同时是Genoptix董事会成员。此前，Nova先生联合创建了Nanogen, Inc.，Nanogen, Inc.是一家分子诊断测试的提供商，她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前，Nova博士担任Selective Genetics的首席运营官，这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.（Eli Lilly & Company的前子公司）担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校（niversity of California, Irvine）获得生物科学学士学位。从加州大学里弗赛德分校（University of California, Riverside）获得生物化学博士学位。
Tina S. Nova has extensive experience in the creation of start up companies and the commercialization of products with a focus on molecular diagnostics. Dr. Nova spent 15 years as the co founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co founded a number of early stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc.- Tina S. Nova博士自2014年4月成为董事会的成员，同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.，这是一家医药实验室诊断公司，她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix，担任Genoptix的首席执行官，同时是Genoptix董事会成员。此前，Nova先生联合创建了Nanogen, Inc.，Nanogen, Inc.是一家分子诊断测试的提供商，她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前，Nova博士担任Selective Genetics的首席运营官，这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.（Eli Lilly & Company的前子公司）担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校（niversity of California, Irvine）获得生物科学学士学位。从加州大学里弗赛德分校（University of California, Riverside）获得生物化学博士学位。
- Tina S. Nova has extensive experience in the creation of start up companies and the commercialization of products with a focus on molecular diagnostics. Dr. Nova spent 15 years as the co founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co founded a number of early stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc.